Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Estradiol Transdermal System USP, 0.014 mg/day, the company announced through an exchange filing.
Estradiol transdermal system is indicated for prevention of postmenopausal osteoporosis. The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).
Estradiol Transdermal System USP, 0.014 mg/day (weekly) had annual sales of USD 1.9 mn in the United States (IQVIA MAT Feb. 2023).
The group now has 363 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
VIDEO: Maharashtra Deputy CM Eknath Shinde Meets PM Modi And HM Amit Shah Amid Mahayuti Strain, Reaffirms Alliance Unity Ahead Of BMC Polls
American Couple Jailed After Arrest On India-Bound Plane In Singapore For Stealing Louis Vuitton, Dior Products Worth ₹65,000 At Airport
Mumbai News: St Xavier's College Cancels Stan Swamy Lecture After ABVP Protest
'I Love His Attitude': Sachin Tendulkar Hails Mohammed Siraj's Heroics After India's Historic Win At The Oval
